This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameLiarozole
Accession NumberDB13066
TypeSmall Molecule
GroupsInvestigational
Description

Liarozole has been used in trials studying the treatment of Ichthyosis, Lamellar.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIK0Q29TGV9Y
CAS number115575-11-6
WeightAverage: 308.77
Monoisotopic: 308.0828741
Chemical FormulaC17H13ClN4
InChI KeyUGFHIPBXIWJXNA-UHFFFAOYSA-N
InChI
InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
IUPAC Name
6-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-1,3-benzodiazole
SMILES
ClC1=CC=CC(=C1)C(N1C=CN=C1)C1=CC=C2N=CNC2=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Liarozole.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Liarozole.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Liarozole.Approved
Choline C 11The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Liarozole.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Liarozole.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Liarozole.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Liarozole.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Liarozole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Liarozole.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Liarozole.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Liarozole.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Liarozole.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Liarozole.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3CompletedTreatmentLamellar Ichthyosis1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0179 mg/mLALOGPS
logP3.65ALOGPS
logP3.48ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)12.2ChemAxon
pKa (Strongest Basic)6.74ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity86.52 m3·mol-1ChemAxon
Polarizability31.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative ParentsChlorobenzenes / N-substituted imidazoles / Aryl chlorides / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Hydrocarbon derivatives
SubstituentsBenzimidazole / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / N-substituted imidazole / Benzenoid / Azole / Imidazole
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 20:36 / Updated on September 01, 2017 12:27